BayardLoweryPowellMD

PubMed

• 1399 citations
  Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B
  Lewis R. Silverman, Erin P. Demakos, Bercedis L. Peterson, Alice B. Kornblith, Jimmie C. Holland
  Journal of Clinical Oncology. 2002-05-15
• 1 citations
  Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia.
  Andrew Stiff, Maarten Fornerod, Bailee N Kain, Deedra Nicolet, Benjamin J Kelly
  Nature Genetics. 2024-11-01
• 189 citations
  Expression and prognostic impact of lncRNAs in acute myeloid leukemia.
  Ramiro Garzon, Stefano Volinia, Dimitrios Papaioannou, Deedra Nicolet, Jessica Kohlschmidt
  Proceedings of the National Academy of Sciences of the United States of America. 2014-12-30

Journal Articles

• NF1 Mutations Are Recurrent in Adult Acute Myeloid Leukemia and Confer Poor Outcome  
  Eunice S Wang, Bayard L Powell, Richard M Stone, John C Byrd, Clara D Bloomfield, Alice Mims, Andrew J Carroll, Jonathan E Kolitz, James S Blachly, Nature
• Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission  
  Kolitz JE, George SL, Benson DM, Maharry K, Marcucci G, Vij R, Powell BL, Allen SL, DeAngelo DJ, Shea TC, Stock W, Bakan CE, Hars V, Hoke E, Bloomfield CD, Caligiuri M..., Cancer, 1/1/2014
• Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score  
  Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH, Kohlschmidt J, Mrozek K, Wu YZ, Bucci D, Curfman JP, Whitman SP, Eisfeld AK, Mendler JH, Schwind S..., J Clin Oncol, 1/1/2014
• Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Grou...  
  Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Blum KA, Powell BL, Shea TC, Nattam S, Hoke E, Cheson BD, Larson RA, Br J Haematol, 1/1/2014
• Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML)  
  Tawfik B, Sliesoraitis S, Lyerly S, Klepin HD, Lawrence J, Isom S, Ellis LR, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee T, Ann Hematol, 1/1/2014
• Prognostic gene mutations and distinct gene-and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8  
  Becker H, Maharry K, Mrozek K, Volinia S, Eisfeld AK, Radmacher MD, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Mendler JH, Wu YZ, Nicolet D, Paschka P, Powell ..., Leukemia, 1/1/2014
• Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype  
  Poire X, Moser BK, Gallagher RE, Laumann K, Bloomfield CD, Powell BL, Koval G, Gulati K, Holowka N, Larson RA, Tallman MS, Appelbaum FR, Sher D, Willman C, Paietta E, ..., Leuk Lymphoma, 1/1/2014
• The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML)  
  Elliot K, Tooze JA, Geller R, Powell BL, Pardee TS, Ritchie E, Kennedy L, Callahan KE, Klepin HD, Leuk Res, 1/1/2014
• Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB ...  
  Wetzler M, Watson D, Stock W, Koval G, Mulkey FA, Hoke EE, McCarty JM, Blum WG, Powell BL, Marcucci G, Bloomfield CD, Linker CA, Larson RA, Haematologica, 1/1/2014
• A phase I study of the first-in-class anti-mitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies  
  Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez RJ, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL, Clin Cancer Res, 1/1/2014
• Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated ac...  
  Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL, Voorhees P, Wang ES, Blum W, Stone RM, Marcucci G, Bloomfield CD, Moser BK,..., J Clin Oncol, 1/1/2013
• Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia Results of Cancer and Leukemia Group B Study 19802  
  Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, Westervelt P, Marcucci G, DeAngelo DJ, Vardiman JW, McDonnell D, Krzysztof M, Bloomfield CD, Larson RA, Cancer, 1/1/2013
• Acute promyelocytic leukemia: progress far and wide  
  Powell BL, Blood, 1/1/2013
• A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal a...  
  Metzeler KH, Maharry K, Kohlschmidt J, Volinia S, Mrozek K, Becker H, Nicolet D, Whitman SP, Mendler JH, Schwind S, Eisfeld AK, Wu YZ, Powell BL, Carter TH, Wetzler M,..., Leukemia, 1/1/2013
• Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients  
  Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrozek K, Nicolet D, Kohlschmidt J, Whitman SP, Mendler JH, Schwind S,Becker H, Eisfeld AK, Carroll AJ, Powell B..., J Clin Oncol, 1/1/2013
• RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA e...  
  Mendler JH, Maharry K, Radmacher MD, Mrozek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moor..., J Clin Oncol, 1/1/2012
• Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia  
  Walter RB, Medeiros BC, Powell BL, Schiffer CA, Appelbaum FR, Estey EH, Haematologica, 1/1/2012
• Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia  
  Marcucci G, Metzeler KH. Schwind S, Becker H, Maharry K, Mrozek K, Radmacher MD, Kohlschmidt J, Nicolet D, Whitman SP, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler ..., J Clin Oncol, 1/1/2012
• Expanding nilotinib access in clinical trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or-intolerant chroni...  
  Nicolini FE, Masszi T, Shen Z, Gallagher NJ, Jootar S, Powell BL, Dorlhaic-Llacer PE, Zheng M, Szczudlo T, Turkina A, Leuk Lymphoma, 1/1/2012
• Expanding nilotinib access in clinical trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or-intolerant chroni...  
  Nicolini FE, Masszi T, Shen Z, Gallagher NJ, Jootar S, Powell BL, Dorlhaic-Llacer PE, Zheng M, Szczudlo T, Turkina A, Cancer, 1/1/2012
• FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group  
  Kutney MA, Moser BK, Laumann K, Feusner JH, Gamis A, Gregory J, Larson RA, Powell BL, Stock W, Willman CL, Woods WG, Meshinchi S, Pediatr Blood Cancer, 1/1/2012
• miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia  
  Eisfeld AK, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Mrozek K, Whitman SP, Metzeler KH, Mendler JH, Wu YZ, Liyanarachchi S, Patel R, Baer M..., Blood, 1/1/2012
• Treatment-influenced associations of PML-RARalpha mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia  
  Gallagher RE, Moser BK, Racevskis J, Poire X, Bloomfield CD, Carroll AJ, Ketterling RP, Roulston D, Schachter-Tokarz E, Zhou DC, Chen IM, Harvey R, Koval G, Sher DA, F..., Blood, 1/1/2012
• The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia  
  Whitman SP, Caligiuri MA, Maharry K, Radmacher MD, Kohlschmidt J, Becker H, Mrozek K, Wu YZ, Schwind S, Metzeler KH, Mendler JH, Wen J, Baer MR, Powell BL, Carter TH, ..., Leukemia, 1/1/2012
• A randomized, controlled trial of panax quinquefolius extract (CVT-E002) to reduce respiratory infection in patients with chronic lymphocytic leukemia  
  High KP, Case D, Hurd D, Powell BL, Lesser G, Falsey AR, Siegel R, Metzner-Sadurski J, Krauss JC, Chinnasami B, Sanders G, Rousey S, Shaw EG, J Support Oncol, 1/1/2012
• Join now to see all

Books/Book Chapters

• Pathy's Principles and Practice of Geriatric Medicine 
  Chapter: Management of myelodysplastic syndromes and acute leukemia in the elderly. 
  Page 375 - 385Klepin HD, Powell BLWiley-Blackwell, West Sussex2012
• American Society of Clinical Oncology Educational Book 
  Chapter: Acute promyelocytic leukemia in 2010. 
  Page 245 - 248Powell, BL2010
• Practical Geriatric Oncology 
  Chapter: Management of myelodysplasia in older adults. 
  Page 221 - 230Klepin HD, Powell BLCambridge University Press2010
• Hazzard's Geriatric Medicine and Gerontology 
  Chapter: White cell disorders. 
  Page 1213 - 1227Klepin HD, Powell BLEditors: Halter JB, Ouslander JG, Tinetti ME, Studenski S, High KP, Asthana S.McGraw-Hill Companies, Inc.Edition 6th,2009
• Cancer Chemotherapy and Biological Response Modifiers 
  Chapter: Diphtheria toxin conjugate therapy of cancer. 
  Page 301 - 313Frankel AR, Powell BL, Lilly MBEditors: Giaccone G, Schilsky R, Sondel P.Elsevier Science B.V., New York2002
• Diagnostic and Therapeutic Advances in Hematologic Malignancies 
  Chapter: Current approaches to acute promyelocytic leukemia. 
  Page 125 - 153Frankel AR, Powell BLEditors: Tallman MS, Gordon LI.Kluwar Academic Publishers1999
• Autologuou Blood and Marrow Transplantation. Proceedings of the Ninth International Symposium, Arlington, Texas 
  Chapter: Presence in pretransplant marrow of abnormal progenitor cell clones that give rise to posttransplant myelodysplasia: implications for high-dose chemoradiotherapy with autologous hematopoietic cell tra 
  Page 483 - 490Radford JE, Abruzzese EA, Pettenati MJ, Rao PN, Rainer RO, Perry JJ, Cruz JM, Powell BL, Miller JS, Vredenburgh JJ, Amadori S, Hurd DDEditors: Dicke KA, Keating A.Carden Jennings Publishing Co., Ltd.1999
• Principles of Geriatric Medicine and Gerontology 
  Chapter: White cell disorders. 
  Page 669 - 678Capizzi RL, Powell BL, Cruz JEditors: Hazzard WR, Andres R, Bieman EL, Blass JP.McGraw-Hill, Inc., New York1989
• Health & Medical Horizons 
  Chapter: Cancer. 
  Page 252 - 256Powell BLMacmillan Educational Company, New York1987
• Understanding Cancer 
  Chapter: Cancer of the central nervous system. 
  Page 147 - 152Powell BLEditors: Atwell BM, Michielutte R.Bowman Gray School of Medicine, Winston-Salem, NC1986
• Join now to see all

Abstracts/Posters

• Evaluating the Utilization of All-Trans Retinoic Acid and Arsenic Trioxide during Consolidation Therapy for Patients Receiving Treatment for Acute Promyelocytic Leukemia
  Bayard L Powell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Multicentre, Open Label, Randomized Phase III Study of Cpi-613¬ (devimistat) in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cyt...
  Bayard L Powell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particular...
  Bayard L Powell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
  Bayard L Powell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Personalized Oncology in Acute Myeloid Leukemia (AML): Validation of the Prognostic Value of the Knowledge Bank Algorithm in Patients (Pts) Treated on Cancer and Leuke...
  Bayard L Powell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)
  Bayard L Powell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphom...
  Bayard L Powell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patient...
  Bayard L Powell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly ActiveClinically Relevant Abstract
  Bayard L Powell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A phase I study of the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.
  Pardee TS, Levitan DA, Hurd DD, Ellis LR, Isom S, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL, J Clin Oncol, 1/1/2013
• Efficacy of the hypomethylating agents as frontline, salvage, or maintenance therapy among older adults with acute myeloid leukemia (AML).
  Tawfik B, Sliesoraitis S, Klepin HD, Lawrence J, Isom S, Ellis LR, Lyerly S, Manuel M, Dralle S, Berenzon DP, Powell BL, Pardee TS, J Clin Oncol, 1/1/2013
• A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal a...
  Metzeler KH, Maharry K, Kohlschmidt J, Volinia S, Mrozek K, Becker H, Nicolet D, Whitman SP, Mendler JH, Schwind S, Eisfeld AK, Wu YZ, Powell BL, Carter TH, Wetzler M,..., Leukemia, 1/1/2013
• Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B study 19802.
  Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, Westervelt P, Marcucci G, Deangelo DJ, Vardiman, JW, McDonnell D, Mrozek K, Bloomfield CD, Larson RA, Cancer, 1/1/2012
• Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.
  Schwind S, Marcucci G, Kohlschmidt J, Radmacher MD, Mrozek K, Maharry K, Becker H, Metzeler KH, Whitman SP, Wu YZ, Powell BL, Baer MR, Kolitz JE, Carroll AJ, Larson RA..., Blood, 1/1/2012
• miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.
  Eisfeld AK, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Mrozek K, Whitman SP, Metzeler KH, Mendler JH, Wu YZ, Liyanarachchi S, Patel R, Baer M..., Blood, 1/1/2012
• Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.
  Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrozek K, Radmacher MD, Kohlschmidt J, Nicolet D, Whitman SP, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler ..., J Clin Oncol, 1/1/2012
• Maintenance therapy with decitabine in younger adults with acute myeloid leukemia (AML) in first remission: a phase II Cancer and Leukemia Group B study (CALGB 10503, ...
  Blum W, Sanford S, Klisovic RB, DeAngelo DJ, Uy G, Powell BL, Stock W, Baer MR, Kolitz JE, Wetzler M, Hoke E, Bloomfield CD, Geyer S, Marcucci G, Stone RM, Larson RA, Blood, 1/1/2012
• Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation-results of CALGB 1...
  Wetzler M, Watson D, Stock W, Owzar K, Koval G, Hoke E, McCarty JM, Blum W, Powell BL, Marcucci G, Bloomfield CD, Linker C, Larson RA, Blood, 1/1/2012
• Adverse prognostic impact of GAS6 expression in De Novo cytogenetically normal acute myeloid leukemia (CN-AML)(CALGB 8461, 9665, 20202; Alliance).
  Whitman S, Kohlschmidt J, Maharry K, Nicolet D, Schwind S, Becker H, Metzeler KH, Mrozek K, Mendler JH, Eisfeld AK, Volinia S, Powell BL, Carter TH, Kolitz JE, Stone R..., Blood, 1/1/2012
• The clinical role of micrornas (miRs) in cytogenetically normal (CN) acute myeloid leukemia (AML): miR-155 upregulation independently identifies high-risk patients (Pts).
  Marcucci G, Maharry K, Metzeler KH, Volinia S, Wu YZ, Krzysztof M, Nicolet D, Kohlschimdt J, Whitman S, Mendler JH, Schwind S, Becker H, Eisfeld AK, Carroll AJ, Powell..., Blood, 1/1/2012
• The prevalence and prognostic significance of polypharmacy in older adults treated for acute myelogenous leukemia (AML).
  Geller R, Tooze JA, Powell BL, Klepin H, J Am Geriatr Soc, 1/1/2011
• Mutations in the TET oncogene family member 2 (TET2) gene refine the new European leukemia net risk classification of primary, cytogenetically normal acute myeloid leu...
  Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolit..., Ann Hematol, 1/1/2011
• A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (AC...
  Stone RM, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon LE, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Miklos E, Horst H, Selleslag..., J Clin Oncol, 1/1/2011
• Persistent hematogone hyperplasia in an adult.
  Eakin S, Lyerly S, Powell B, Grier DD, Arch Pathol Lab Med, 1/1/2011
• ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal acute myeloid leukemia within the European LeukemiaNet "favorable" ...
  Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrozek K, Nicolet D, Whitman SP, Wu YZ, Schwind S, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE,..., Blood, 1/1/2011
• Join now to see all

Lectures

• A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML)... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Therapeutic Manipulation of Cancer Cell Metabolism with the Mitochondrial Metabolism Inhibitor Cpi-613 in Addition to Chemotherapy Abrogates the Adverse Prognostic Eff... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mutations in Genes Associated with Familial Predisposition to Myeloid Neoplasms: Their Frequency and Associations with Pretreatment Characteristics in Adult Patients (... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Genome-Wide Association Study (GWAS) Identifies a Significant Acute Myeloid Leukemia (AML) Susceptibility Locus Near BICRA 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical and Molecular Characteristics of Acute Myeloid Leukemia (AML) Patients with TP53 Mutations and TP73 Mutations 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Prognostic and Biologic Significance of Transfer RNA-Derived Small RNAs (tsRNAs) Expression in Younger Adult Patients (Pts) with Cytogenetically Normal Acute Myeloid L... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• "New therapies and patient treatment options." 
  Winston-Salem, NC - 7/19/2014
• Chair: "34th Annual Symposium" 
  Hilton Head, SC - 11/4/2013
• "Myelodysplastic Syndrome (MDS)" 
  Asheville, NC - 11/3/2012
• Chair: "33rd Annual Symposium" 
  Asheville, NC - 11/2/2012
• Adding mercaptopurine and methotrexate to alternate week ATRA maintenance therapy does not improve the outcome for adults with acute promyelocytic leukemia (APL) in fi... 
  12/12/2011
• Chair: "32nd Annual Symposium" 
  Myrtle Beach, SC - 9/15/2011
• "Myeloid Leukemias Acute and Chronic" 
  Charlotte, NC - 2/26/2011
• "Acute Myeloid Leukemia" 
  Concord, NC - 11/3/2010
• Internal Medicine Grand Rounds: "Acute Promyelocytic Leukemia 2010" 
  Wake Forest University School of Medicine, Winston-Salem, NC - 10/28/2010
• Chair: "31st Annual Symposium" 
  Asheville, NC - 8/26/2010
• Speaker, Education Session, "Curable and highly treatable leukemias: How do I optimize outcome?" 
  Chicago, IL - 6/5/2010
• Hematology Grand Rounds: "Acute promyelocytic leukemia: What we learned from C9710." 
  University of Texas M.D. Anderson Cancer Center, Houston, TX - 4/21/2010
• Nilotinib responses and tolerability confirmed in North American & NBSP; patients with chronic myeloid leukemia (CML) from ENACT (expanding Nilotinib access in clinica... 
  New Orleans, LA - 12/7/2009
• Risk adapted treatment of APL, US trials. Novel insights in the treatment of APL: Clinical integration of risk directed therapies. 
  New Orleans, LA - 12/4/2009
• Reviewer, "Acute Myeloid Leukemia." 
  New Orleans, LA - 12/3/2009
• North American Leukemia Intergroup C9710: arsenic trioxide consolidation for adults with newly diagnosed APL. 
  New Orleans, LA - 12/3/2009
• "Advances in the Management of Acute Promyelocytic Leukemia" 
  Hackensack, NJ - 11/19/2009
• Chair: "30th Annual Symposium" 
  Myrtle Beach, SC - 10/9/2009
• Arsenic trioxide consolidation therapy for adults with APL: North American Leukemia Intergroup Protocol C9710. 
  Rome, Italy - 9/26/2009
• Join now to see all

Other

• "Delivering Bad News" (Education Tape) 
  Richard McQuellon, PhD, Bayard Lowery Powell, MD
  1/1/1998